Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:40:35.275Z.
Calculation as of: 2026-10-06T13:40:35.275Z.
Quote observation: 2026-10-06T13:39:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b909c1583fef9061a4d716d1bfa7e8c39158eca830282836b9decd9e758125
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$797661.00
PS Ratio
N/A
TTM Avg
2215.39
3Y Avg
2233.86
5Y Avg
2233.86
Market Cap
$883067.00
PS Ratio
N/A
TTM Avg
86.14
3Y Avg
51.38
5Y Avg
839.91
Market Cap
$893920.00
PS Ratio
N/A
TTM Avg
48450.87
3Y Avg
43764.18
5Y Avg
43764.18
Market Cap
$1.03M
PS Ratio
10.56
TTM Avg
20733.20
3Y Avg
20733.20
5Y Avg
20733.20
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akanda Corp. (AKAN) | $61573.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $559702.00 | 0.08 | 5.16 | 225.96 | 406.71 |
| CDT Equity Inc. (CDT)vs › | $685717.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $797661.00 | N/A | 2215.39 | 2233.86 | 2233.86 |
| Bone Biologics Corporation (BBLG)vs › | $867353.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $883067.00 | N/A | 86.14 | 51.38 | 839.91 |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | 48450.87 | 43764.18 | 43764.18 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | 10.56 | 20733.20 | 20733.20 | 20733.20 |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
Half-year reporter: no trailing two-half-year basis, because the newest half-year cannot be compared with the two half-years before it (an earlier half-year's revenue is not positive), so the half-year figures cannot be used until the full year is reported.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
